Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Z. Reiss, F. Rob, M. Kolar, D. Schierova, J. Kreisinger, Z. Jackova, R. Roubalova, S. Coufal, M. Mihula, T. Thon, L. Bajer, M. Novakova, M. Vasatko, K. Kostovcikova, N. Galanova, M. Lukas, M. Kverka, J. Tresnak Hercogova, H. Tlaskalova-Hogenova,...

. 2022 ; 12 (-) : 1064537. [pub] 20230110

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23004623

Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of patients suffer from unpredictable skin adverse events (SkAE). For this purpose, we analyzed temporal dynamics of skin microbiota and serum markers of inflammation and epithelial barrier integrity during anti-TNF therapy and SkAE manifestation in IBD patients. We observed that the skin microbiota signature of IBD patients differs markedly from healthy subjects. In particular, the skin microbiota of CD patients differs significantly from that of UC patients and healthy subjects, mainly in the retroauricular crease. In addition, we showed that anti-TNF-related SkAE are associated with specific shifts in skin microbiota profile and with a decrease in serum levels of L-FABP and I-FABP in IBD patients. For the first time, we showed that shifts in microbial composition in IBD patients are not limited to the gut and that skin microbiota and serum markers of the epithelium barrier may be suitable markers of SkAE during anti-TNF therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004623
003      
CZ-PrNML
005      
20230425171629.0
007      
ta
008      
230418s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcimb.2022.1064537 $2 doi
035    __
$a (PubMed)36704107
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Reiss, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
245    10
$a Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy / $c Z. Reiss, F. Rob, M. Kolar, D. Schierova, J. Kreisinger, Z. Jackova, R. Roubalova, S. Coufal, M. Mihula, T. Thon, L. Bajer, M. Novakova, M. Vasatko, K. Kostovcikova, N. Galanova, M. Lukas, M. Kverka, J. Tresnak Hercogova, H. Tlaskalova-Hogenova, Z. Jiraskova Zakostelska
520    9_
$a Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of patients suffer from unpredictable skin adverse events (SkAE). For this purpose, we analyzed temporal dynamics of skin microbiota and serum markers of inflammation and epithelial barrier integrity during anti-TNF therapy and SkAE manifestation in IBD patients. We observed that the skin microbiota signature of IBD patients differs markedly from healthy subjects. In particular, the skin microbiota of CD patients differs significantly from that of UC patients and healthy subjects, mainly in the retroauricular crease. In addition, we showed that anti-TNF-related SkAE are associated with specific shifts in skin microbiota profile and with a decrease in serum levels of L-FABP and I-FABP in IBD patients. For the first time, we showed that shifts in microbial composition in IBD patients are not limited to the gut and that skin microbiota and serum markers of the epithelium barrier may be suitable markers of SkAE during anti-TNF therapy.
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory TNF $7 D000079424
650    12
$a idiopatické střevní záněty $x farmakoterapie $7 D015212
650    12
$a Crohnova nemoc $7 D003424
650    12
$a ulcerózní kolitida $7 D003093
650    12
$a mikrobiota $7 D064307
650    _2
$a biologické markery $7 D015415
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rob, Filip $u Department of Dermatovenerology, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czechia
700    1_
$a Kolar, Martin $u IBD Clinical and Research Centre ISCARE a.s., Prague, Czechia
700    1_
$a Schierova, Dagmar $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Kreisinger, Jakub $u Department of Zoology, Faculty of Science, Charles University, Prague, Czechia
700    1_
$a Jackova, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Roubalova, Radka $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Coufal, Stepan $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Mihula, Martin $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Thon, Tomas $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Bajer, Lukas $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia $u Department of Gastroenterology and Hepatology, Institute of Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Novakova, Michaela $u Department of Dermatovenerology, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czechia
700    1_
$a Vasatko, Martin $u IBD Clinical and Research Centre ISCARE a.s., Prague, Czechia
700    1_
$a Kostovcikova, Klara $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Galanova, Natalie $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre ISCARE a.s., Prague, Czechia $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Kverka, Miloslav $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Tresnak Hercogova, Jana $u Department of Dermatovenerology, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czechia $u Prof. Hercogova Dermatology, Prague, Czechia
700    1_
$a Tlaskalova-Hogenova, Helena $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Jiraskova Zakostelska, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czechia
773    0_
$w MED00182987 $t Frontiers in cellular and infection microbiology $x 2235-2988 $g Roč. 12, č. - (2022), s. 1064537
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36704107 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171625 $b ABA008
999    __
$a ok $b bmc $g 1924987 $s 1190832
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 12 $c - $d 1064537 $e 20230110 $i 2235-2988 $m Frontiers in cellular and infection microbiology $n Front Cell Infect Microbiol $x MED00182987
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options